Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rotigotine (N-0923) 是多巴胺受体激动剂,是5-HT1A receptor 的部分激动剂,以及α2B-肾上腺素受体的拮抗剂,用于治疗帕金森病和不宁腿综合征。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 178 | 现货 | ||
5 mg | ¥ 393 | 现货 | ||
10 mg | ¥ 627 | 现货 | ||
25 mg | ¥ 1,260 | 现货 | ||
50 mg | ¥ 2,320 | 现货 | ||
100 mg | ¥ 3,280 | 现货 | ||
200 mg | ¥ 4,690 | 现货 | ||
500 mg | ¥ 7,220 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | Rotigotine (N-0923) is a non-ergot dopamine receptor agonist used in the therapy of Parkinson disease and restless leg syndrome. Administered as a once-daily transdermal patch, Rotigotine has not been associated with serum enzyme elevations during treatment or with episodes of clinically apparent liver injury. |
靶点活性 | 5-HT7 receptor:86 nM (Ki), D1 receptor:83 nM (Ki), D4 receptor:4-15 nM (Ki), D3 receptor:0.71 nM (Ki), 5-HT1A receptor:30 nM (Ki), D5 receptor:4-15 nM (Ki), D2 receptor:4-15 nM (Ki) |
体外活性 | The selectivity of Rotigotine for D3 (pKi 9.2) receptors is higher 10-fold than D2/D4/D5 (pKi 8.5-8.0) and 100-fold than D1 receptors (pKi 7.2). Rotigotine (10 μM) decreases the number of THir neurons by 40% in primary mesencephalic cell culture. In functional studies, Rotigotine behaves as a full agonist at all dopamine receptors but notably, the potency for stimulation of D1 receptors is similar to that for D2/D3 receptors (pEC50 respectively: 9.0, 9.4-8.6, 9.7). Rotigotine (0.01 μM) slightly protects dopaminergic neurons against MPP+ toxicity, significantly protects dopaminergic neurons against rotenone-induced cell death, and significantly inhibits ROS production by rotenone. |
体内活性 | In primed rats, Rotigotine (0.035/0.1/0.35 mg/kg) dose-dependently induces contralateral turning behavior. In drug-naive rats, the turning behavior induced by Rotigotine, either alone or in combination with SCH 39166, is reduced compared to primed rats. |
激酶实验 | Binding assays are performed in 96-well polypropylene tubes in a final volume of 2?mL for D1 and D4 membranes and 1?mL for D2, D3 and D5 membranes containing: 50?μL radioligand, 10?μL drug/buffer/non-specific binding, buffer (final concentration 50?mM Tris-HCl pH 7.4, MgCl2 2?mM) and membranes (5?μg protein for D2 and D3 and 25?μg protein for D1 and D5). Following 120?min of incubation at 25°C, bound radioligand is determined by rapid vacuum filtration through A/C glass fibre filters presoaked in 0.1% polyethylenimine. The filters are washed four times with 2?mL ice-cold ishing buffer (Tris-HCl 50?mM, pH?7.4 at 4°C) and retained radioactivity is determined by liquid scintillation counting. |
别名 | Neupro, N-0923, 罗替戈汀, N-0437, SPM 962 |
分子量 | 315.47 |
分子式 | C19H25NOS |
CAS No. | 99755-59-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 59 mg/mL (187 mM)
Ethanol: 59 mg/mL (187 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.1699 mL | 15.8494 mL | 31.6987 mL | 79.2468 mL |
5 mM | 0.634 mL | 3.1699 mL | 6.3397 mL | 15.8494 mL | |
10 mM | 0.317 mL | 1.5849 mL | 3.1699 mL | 7.9247 mL | |
20 mM | 0.1585 mL | 0.7925 mL | 1.5849 mL | 3.9623 mL | |
50 mM | 0.0634 mL | 0.317 mL | 0.634 mL | 1.5849 mL | |
100 mM | 0.0317 mL | 0.1585 mL | 0.317 mL | 0.7925 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rotigotine- 99755-59-6 GPCR/G Protein Neuroscience 5-HT Receptor Dopamine Receptor Adrenergic Receptor Rotigotine dopamine Neupro 5-HT1A receptor N0437 Serotonin Receptor Beta Receptor N-0923 N 0437 N0923 5-hydroxytryptamine Receptor 罗替戈汀 α2B-adrenergic N-0437 Inhibitor SPM962 inhibit SPM 962 SPM-962 N 0923 inhibitor